CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG ...

Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 49.92% Upside As of ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $60.62, moving -2.38% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.55% for ...